In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period

Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2015-10, Vol.27 (5), p.266-270
Main Authors: Spiliopoulou, Anastasia, Jelastopulu, Eleni, Vamvakopoulou, Sofia, Bartzavali, Christina, Kolonitsiou, Fevronia, Anastassiou, Evangelos D., Christofidou, Myrto
Format: Article
Language:English
Subjects:
A. baumanni
Acinetobacter baumannii - drug effects
Acinetobacter baumannii - isolation & purification
Acinetobacter Infections - drug therapy
Acinetobacter Infections - microbiology
Anti-Bacterial Agents - pharmacology
Bloodstream infections
Colistin
Colistin - pharmacology
Drug Resistance, Multiple, Bacterial - drug effects
Humans
In Vitro Techniques
Microbial Sensitivity Tests
Minocycline - analogs & derivatives
Minocycline - pharmacology
Multidrug resistance
Tertiary Care Centers
Tigecycline
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113
cites cdi_FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113
container_end_page 270
container_issue 5
container_start_page 266
container_title Journal of chemotherapy (Florence)
container_volume 27
creator Spiliopoulou, Anastasia
Jelastopulu, Eleni
Vamvakopoulou, Sofia
Bartzavali, Christina
Kolonitsiou, Fevronia
Anastassiou, Evangelos D.
Christofidou, Myrto
description Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®2 system, whereas, susceptibility testing by VITEK2, Kirby-Bauer disc system, and Etest strips. Interpretation of results was based on CLSI criteria and, regarding tigecycline, Food and Drug Administration (FDA) criteria. Between 2006 and 2013, 441 among 7088 BSI cases were attributed to A. baumannii. Of all isolates, 92·1% were resistant to more than three classes of antibiotics and 79·4% were resistant to all but one or two categories of antimicrobials. Resistance to ampicillin-sulbactam, meropenem, gentamicin, ciprofloxacin, minocycline, and tigecycline increased during the study period (P
doi_str_mv 10.1179/1973947814Y.0000000193
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1705476223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3780079891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113</originalsourceid><addsrcrecordid>eNqFkU1rHSEUhqU0NCHJXwhCN93MrV8z6vIS-hEIdNNCshLH0YvB0Vt12s6_r8NNP-imZ3MOnOd9j_ICcIPRDmMu32LJqWRcYPa4Q6fCkr4AF9ui2zYv24wJ6hCSD-fgupSnDRpI0w2vwDlhgnAp-gvw4y7Cb77mBLWpvk0rTA5Wf7BmNcFHC3WcoEnBl-oj1AftY6lwv4OjXmYdo_dw47zRAY4hpanUbPUMfUlBV1vgtGQfD80Gim61OsOjzT5NV-DM6VDs9XO_BF_ev_t8-7G7__Th7nZ_3xkqee2YMcwR3Mtecsd7wxCdnHGj0O2Xo-MTMgNhBhEtibMIMc6tcIIKKgU1GNNL8Obke8zp62JLVbMvxoago01LUZijnvGBENrQ1_-gT2nJsb1uoxijw0B5o4YTZXIqJVunjtnPOq8KI7XFo_6KR_2Jpwlvnu2XcbbTb9mvMBqwPwE-upRn_T3lMKmq15CyyzoaXxT9z5Gfxh-fGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1704436637</pqid></control><display><type>article</type><title>In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Spiliopoulou, Anastasia ; Jelastopulu, Eleni ; Vamvakopoulou, Sofia ; Bartzavali, Christina ; Kolonitsiou, Fevronia ; Anastassiou, Evangelos D. ; Christofidou, Myrto</creator><creatorcontrib>Spiliopoulou, Anastasia ; Jelastopulu, Eleni ; Vamvakopoulou, Sofia ; Bartzavali, Christina ; Kolonitsiou, Fevronia ; Anastassiou, Evangelos D. ; Christofidou, Myrto</creatorcontrib><description>Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®2 system, whereas, susceptibility testing by VITEK2, Kirby-Bauer disc system, and Etest strips. Interpretation of results was based on CLSI criteria and, regarding tigecycline, Food and Drug Administration (FDA) criteria. Between 2006 and 2013, 441 among 7088 BSI cases were attributed to A. baumannii. Of all isolates, 92·1% were resistant to more than three classes of antibiotics and 79·4% were resistant to all but one or two categories of antimicrobials. Resistance to ampicillin-sulbactam, meropenem, gentamicin, ciprofloxacin, minocycline, and tigecycline increased during the study period (P&lt;0·05). Although tigecycline resistance was low during the first 4 years of the study (25·5%), it increased up to 66·5% during 2010-2013. No isolate was colistin resistant.</description><identifier>ISSN: 1120-009X</identifier><identifier>EISSN: 1973-9478</identifier><identifier>DOI: 10.1179/1973947814Y.0000000193</identifier><identifier>PMID: 24827985</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>A. baumanni ; Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - isolation &amp; purification ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - microbiology ; Anti-Bacterial Agents - pharmacology ; Bloodstream infections ; Colistin ; Colistin - pharmacology ; Drug Resistance, Multiple, Bacterial - drug effects ; Humans ; In Vitro Techniques ; Microbial Sensitivity Tests ; Minocycline - analogs &amp; derivatives ; Minocycline - pharmacology ; Multidrug resistance ; Tertiary Care Centers ; Tigecycline ; Time Factors</subject><ispartof>Journal of chemotherapy (Florence), 2015-10, Vol.27 (5), p.266-270</ispartof><rights>2015 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia 2015</rights><rights>(©) 2015 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113</citedby><cites>FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24827985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spiliopoulou, Anastasia</creatorcontrib><creatorcontrib>Jelastopulu, Eleni</creatorcontrib><creatorcontrib>Vamvakopoulou, Sofia</creatorcontrib><creatorcontrib>Bartzavali, Christina</creatorcontrib><creatorcontrib>Kolonitsiou, Fevronia</creatorcontrib><creatorcontrib>Anastassiou, Evangelos D.</creatorcontrib><creatorcontrib>Christofidou, Myrto</creatorcontrib><title>In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period</title><title>Journal of chemotherapy (Florence)</title><addtitle>J Chemother</addtitle><description>Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®2 system, whereas, susceptibility testing by VITEK2, Kirby-Bauer disc system, and Etest strips. Interpretation of results was based on CLSI criteria and, regarding tigecycline, Food and Drug Administration (FDA) criteria. Between 2006 and 2013, 441 among 7088 BSI cases were attributed to A. baumannii. Of all isolates, 92·1% were resistant to more than three classes of antibiotics and 79·4% were resistant to all but one or two categories of antimicrobials. Resistance to ampicillin-sulbactam, meropenem, gentamicin, ciprofloxacin, minocycline, and tigecycline increased during the study period (P&lt;0·05). Although tigecycline resistance was low during the first 4 years of the study (25·5%), it increased up to 66·5% during 2010-2013. No isolate was colistin resistant.</description><subject>A. baumanni</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - isolation &amp; purification</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bloodstream infections</subject><subject>Colistin</subject><subject>Colistin - pharmacology</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Microbial Sensitivity Tests</subject><subject>Minocycline - analogs &amp; derivatives</subject><subject>Minocycline - pharmacology</subject><subject>Multidrug resistance</subject><subject>Tertiary Care Centers</subject><subject>Tigecycline</subject><subject>Time Factors</subject><issn>1120-009X</issn><issn>1973-9478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFkU1rHSEUhqU0NCHJXwhCN93MrV8z6vIS-hEIdNNCshLH0YvB0Vt12s6_r8NNP-imZ3MOnOd9j_ICcIPRDmMu32LJqWRcYPa4Q6fCkr4AF9ui2zYv24wJ6hCSD-fgupSnDRpI0w2vwDlhgnAp-gvw4y7Cb77mBLWpvk0rTA5Wf7BmNcFHC3WcoEnBl-oj1AftY6lwv4OjXmYdo_dw47zRAY4hpanUbPUMfUlBV1vgtGQfD80Gim61OsOjzT5NV-DM6VDs9XO_BF_ev_t8-7G7__Th7nZ_3xkqee2YMcwR3Mtecsd7wxCdnHGj0O2Xo-MTMgNhBhEtibMIMc6tcIIKKgU1GNNL8Obke8zp62JLVbMvxoago01LUZijnvGBENrQ1_-gT2nJsb1uoxijw0B5o4YTZXIqJVunjtnPOq8KI7XFo_6KR_2Jpwlvnu2XcbbTb9mvMBqwPwE-upRn_T3lMKmq15CyyzoaXxT9z5Gfxh-fGA</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Spiliopoulou, Anastasia</creator><creator>Jelastopulu, Eleni</creator><creator>Vamvakopoulou, Sofia</creator><creator>Bartzavali, Christina</creator><creator>Kolonitsiou, Fevronia</creator><creator>Anastassiou, Evangelos D.</creator><creator>Christofidou, Myrto</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period</title><author>Spiliopoulou, Anastasia ; Jelastopulu, Eleni ; Vamvakopoulou, Sofia ; Bartzavali, Christina ; Kolonitsiou, Fevronia ; Anastassiou, Evangelos D. ; Christofidou, Myrto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>A. baumanni</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - isolation &amp; purification</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bloodstream infections</topic><topic>Colistin</topic><topic>Colistin - pharmacology</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Microbial Sensitivity Tests</topic><topic>Minocycline - analogs &amp; derivatives</topic><topic>Minocycline - pharmacology</topic><topic>Multidrug resistance</topic><topic>Tertiary Care Centers</topic><topic>Tigecycline</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spiliopoulou, Anastasia</creatorcontrib><creatorcontrib>Jelastopulu, Eleni</creatorcontrib><creatorcontrib>Vamvakopoulou, Sofia</creatorcontrib><creatorcontrib>Bartzavali, Christina</creatorcontrib><creatorcontrib>Kolonitsiou, Fevronia</creatorcontrib><creatorcontrib>Anastassiou, Evangelos D.</creatorcontrib><creatorcontrib>Christofidou, Myrto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of chemotherapy (Florence)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spiliopoulou, Anastasia</au><au>Jelastopulu, Eleni</au><au>Vamvakopoulou, Sofia</au><au>Bartzavali, Christina</au><au>Kolonitsiou, Fevronia</au><au>Anastassiou, Evangelos D.</au><au>Christofidou, Myrto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period</atitle><jtitle>Journal of chemotherapy (Florence)</jtitle><addtitle>J Chemother</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>27</volume><issue>5</issue><spage>266</spage><epage>270</epage><pages>266-270</pages><issn>1120-009X</issn><eissn>1973-9478</eissn><abstract>Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®2 system, whereas, susceptibility testing by VITEK2, Kirby-Bauer disc system, and Etest strips. Interpretation of results was based on CLSI criteria and, regarding tigecycline, Food and Drug Administration (FDA) criteria. Between 2006 and 2013, 441 among 7088 BSI cases were attributed to A. baumannii. Of all isolates, 92·1% were resistant to more than three classes of antibiotics and 79·4% were resistant to all but one or two categories of antimicrobials. Resistance to ampicillin-sulbactam, meropenem, gentamicin, ciprofloxacin, minocycline, and tigecycline increased during the study period (P&lt;0·05). Although tigecycline resistance was low during the first 4 years of the study (25·5%), it increased up to 66·5% during 2010-2013. No isolate was colistin resistant.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>24827985</pmid><doi>10.1179/1973947814Y.0000000193</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1120-009X
ispartof Journal of chemotherapy (Florence), 2015-10, Vol.27 (5), p.266-270
issn 1120-009X
1973-9478
language eng
recordid cdi_proquest_miscellaneous_1705476223
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects A. baumanni
Acinetobacter baumannii - drug effects
Acinetobacter baumannii - isolation & purification
Acinetobacter Infections - drug therapy
Acinetobacter Infections - microbiology
Anti-Bacterial Agents - pharmacology
Bloodstream infections
Colistin
Colistin - pharmacology
Drug Resistance, Multiple, Bacterial - drug effects
Humans
In Vitro Techniques
Microbial Sensitivity Tests
Minocycline - analogs & derivatives
Minocycline - pharmacology
Multidrug resistance
Tertiary Care Centers
Tigecycline
Time Factors
title In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A22%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20tigecycline%20and%20colistin%20against%20A.%20baumannii%20clinical%20bloodstream%20isolates%20during%20an%208-year%20period&rft.jtitle=Journal%20of%20chemotherapy%20(Florence)&rft.au=Spiliopoulou,%20Anastasia&rft.date=2015-10-01&rft.volume=27&rft.issue=5&rft.spage=266&rft.epage=270&rft.pages=266-270&rft.issn=1120-009X&rft.eissn=1973-9478&rft_id=info:doi/10.1179/1973947814Y.0000000193&rft_dat=%3Cproquest_pubme%3E3780079891%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c397t-4cc4f2159597f75c403dfcfb8a478bf7d0c624c02a92fe00477e8f8383983c113%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1704436637&rft_id=info:pmid/24827985&rfr_iscdi=true